ASX:TLXBiotechs
Assessing Telix Pharmaceuticals (ASX:TLX) Valuation After Key China And US Prostate Cancer Milestones
Telix Pharmaceuticals (ASX:TLX) is back in focus after Chinese regulators accepted a New Drug Application for its Illuccix prostate cancer imaging agent, and the company reported first patient dosing in a US Phase 3 diagnostic trial.
See our latest analysis for Telix Pharmaceuticals.
Despite the regulatory momentum in China and the US, Telix’s share price return over the past 90 days shows a 34.31% decline, contributing to a 60.23% drop in 1-year total shareholder return. However, the 5-year...